As of 2025-09-18, the EV/EBITDA ratio of Altimmune Inc (ALT) is -1.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 146.32 mil USD. Altimmune's TTM EBITDA according to its financial statements is -94.18 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 14.7x | 13.6x |
| Forward P/E multiples | 15.1x - 34.0x | 19.2x |
| Fair Price | (14.16) - (13.75) | (15.59) |
| Upside | -496.6% - -485.2% | -536.6% |
| Date | EV/EBITDA |
| 2025-09-16 | -1.61 |
| 2025-09-15 | -1.57 |
| 2025-09-12 | -1.62 |
| 2025-09-11 | -1.67 |
| 2025-09-10 | -1.65 |
| 2025-09-09 | -1.75 |
| 2025-09-08 | -1.68 |
| 2025-09-05 | -1.75 |
| 2025-09-04 | -1.54 |
| 2025-09-03 | -1.66 |
| 2025-09-02 | -1.72 |
| 2025-08-29 | -1.80 |
| 2025-08-28 | -1.68 |
| 2025-08-27 | -1.65 |
| 2025-08-26 | -1.43 |
| 2025-08-25 | -1.38 |
| 2025-08-22 | -1.53 |
| 2025-08-21 | -1.52 |
| 2025-08-20 | -1.61 |
| 2025-08-19 | -1.60 |
| 2025-08-18 | -1.54 |
| 2025-08-15 | -1.61 |
| 2025-08-14 | -1.66 |
| 2025-08-13 | -1.71 |
| 2025-08-12 | -1.60 |
| 2025-08-11 | -1.38 |
| 2025-08-08 | -1.44 |
| 2025-08-07 | -1.51 |
| 2025-08-06 | -1.58 |
| 2025-08-05 | -1.65 |
| 2025-08-04 | -1.56 |
| 2025-08-01 | -1.59 |
| 2025-07-31 | -1.67 |
| 2025-07-30 | -1.63 |
| 2025-07-29 | -1.80 |
| 2025-07-28 | -1.98 |
| 2025-07-25 | -2.03 |
| 2025-07-24 | -2.06 |
| 2025-07-23 | -2.23 |
| 2025-07-22 | -2.14 |
| 2025-07-21 | -2.00 |
| 2025-07-18 | -2.03 |
| 2025-07-17 | -2.00 |
| 2025-07-16 | -2.13 |
| 2025-07-15 | -2.13 |
| 2025-07-14 | -2.20 |
| 2025-07-11 | -2.09 |
| 2025-07-10 | -2.33 |
| 2025-07-09 | -2.65 |
| 2025-07-08 | -2.50 |